About ColoWatch
ColoWatch helps imaging centers screen people for colon and rectal cancer without sedation. It uses low-dose computed tomography, or CT, scans to create detailed views of the colon. ColoWatch calls this virtual colonoscopy. Each facility follows the same protocol and quality checks. Exams travel through a secure cloud system to board-certified radiologists trained on ColoWatch's viewing software. The service needs no on-site radiologist. ColoWatch trains CT technologists, and most exams take 15 minutes.
ColoWatch is based in Gaithersburg, Maryland. Co-founder and chief executive officer Bikram Bakshi previously led the turnaround of Healthcare.gov. Co-founder and president Mark Klein practiced diagnostic radiology near Washington for more than 40 years. He has performed over 8,000 virtual colonoscopy screening studies.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Sep 24, 2026 | Oct 8, 2026amended Nov 9, 2026 | $1,435,000of $3.0M target | 11 | $130K | Debt, OptionsRule 506(b) | Form D/A ↗2 earlier filings |
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Why Investors Backed ColoWatch
ColoWatch packages virtual colonoscopy for imaging centers as a standardized service. Facilities perform the scans, while remote specialists review the images through cloud software. The model seeks to expand colorectal cancer screening without requiring sedation or an on-site radiologist.
The problem it targets
ColoWatch argues that screening must expand because colorectal cancer risk is rising in younger people, while many patients remain unscreened. It also points to a shortage of gastroenterologists. Its comparison reports seven deaths per 100,000 traditional colonoscopies and serious complications in four to five per 1,000 patients. The same table gives stool tests a 20% to 42% detection rate for precancerous polyps.
What the product does
Radiologists may review an exam up to 10 times using high-resolution three-dimensional images. The cited New England Journal of Medicine study reports 95% cancer detection and 94% detection of precancerous polyps. Positive findings for a significant polyp or colorectal cancer are correct more than 95% of the time. Low-dose scans may also reveal lung cancer, kidney cancer and aortic aneurysms.
Progress so far
Bracco Diagnostics partnered with ColoWatch in November 2024 to help imaging facilities add virtual colonoscopy. The collaboration was intended to make implementation easier, especially in underserved communities. ColoWatch joined NVIDIA Inception in June 2026. The program offers technical tools, training and business support; ColoWatch plans to use them for infrastructure, education and partner operations.
How the market is moving
Medicare began covering virtual colonoscopy screening in January 2025. Even so, just 1.7% of eligible adults report using it. American Cancer Society figures cited in the Bracco announcement show that only 20% of people ages 45 to 49 undergo colorectal screening. The same figures project a 140% increase in colorectal cancer among people under 50 by 2030.
We wrote this summary from public statements by ColoWatch and its investors. It is not investment advice.
ColoWatch in the News
Leadership Team
Executive officers and directors listed on ColoWatch's Form D filed Nov 9, 2026.
Sources
- SECColoWatch, Inc. /MD/ Form D/A, filed Oct 19, 2026
- SECColoWatch, Inc. /MD/ Form D, filed Oct 8, 2026
- SECColoWatch, Inc. /MD/ filing history
- CompanyAbout Us | ColoWatch
- CompanyInsights & Research | ColoWatch
- CompanyColoWatch Announces Membership in the NVIDIA Inception Program
- CompanyColoWatch and Bracco Diagnostics Announce Partnership
- PressColoWatch and Bracco Diagnostics Announce Partnership